







Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculo-
sis. It is estimated that about one-third of the world’s population is latently infected 
with M. tuberculosis and that TB causes the death of 1.5 million people per year [1,2]. 
Unfortunately, the efficacy of the current TB vaccine is limited, thus development of 
an effective vaccine against TB is urgently required.
 The M. bovis bacillus Calmette-Guérin (BCG) strain is used in the current TB vac-
cine, which has been used since 1921 [3,4]. Whereas BCG is effective for the preven-
tion of severe forms of TB in children, such as miliary TB and TB meningitis [5,6], re-
ports of its efficacy for the prevention of adult pulmonary TB are inconsistent [7,8]. In 
fact, the efficacy varies from 0% to 80% between studies, and it is the lowest in develop-
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Purpose: T cell-mediated immune responses, and particularly activation of polyfunctional T 
cells that simultaneously produce multiple cytokines, are necessary for the control of Myco­
bacterium tuberculosis. In the present study, we examined if DNA immunization of Mycobacte­
rium tuberculosis resuscitation-promoting factor B (RpfB) elicits polyfunctional T cell respons-
es in mice.
Materials and Methods: C57BL/6 mice were immunized intramuscularly three times, at 3-week 
intervals, with RpfB-expressing plasmid DNA. For comparison, protein immunization was per-
formed with recombinant RpfB in control mice. After immunization, RpfB-specific T cell re-
sponses were assessed by interferon-γ (IFN-γ) enzyme-linked immunosorbent spot assay and 
intracellular cytokine staining (ICS), and T cell polyfunctionality was assessed from the ICS data.
Results: RpfB DNA immunization induced not only humoral immune responses, but also CD8+ 
and CD4+ T cell responses. Immunodominant T-cell epitopes were identified within RpfB by 
assays with overlapping peptides. RpfB DNA immunization elicited a polyfunctional CD8+ T cell 
response that was dominated by a functional phenotype of IFN-γ+/TNF-α+/IL-2-/CD107a+.
Conclusion: RpfB DNA immunization elicits polyfunctional CD8+ T cell responses, suggesting 
that RpfB DNA immunization might induce protective immunity against tuberculosis.
Keywords: Tuberculosis, Resuscitation-promoting factor B, Polyfunctional T cells, DNA vac-
cines
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ing countries where protection against TB is the most needed 
[7,8]. 
 For effective control of M. tuberculosis infection, T cell-me-
diated immune responses are essential [9,10] and thus, T cell 
activation following vaccination is considered to be a key re-
quirement for generating protective immunity against TB. In 
particular, CD4+ T helper 1 (Th1) cells play a major role in im-
mune responses against TB by secreting cytokines such as 
interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) [11-
14], which activate macrophages. In addition, CD8+ T cells al-
so make important contributions to the protective immune 
responses against TB, as they not only secrete IFN-γ and TNF-α, 
but also lyse infected macrophages and epithelial cells [15-17].
 Recently, the importance of activating polyfunctional T 
cells, which simultaneously produce multiple cytokines, has 
been emphasized in vaccine development. Initially, the sig-
nificance of polyfunctional T cells was proven by a study that 
showed that the degree of vaccine protection against Leish-
mania major was predicted by the frequency of polyfunc-
tional Th1 cells simultaneously secreting IFN-γ, TNF-α, and 
interleukin-2 (IL-2) [18]. In TB, the presence of polyfunction-
al CD4+ Th1 cells correlates with protection against M. tuber-
culosis challenge in mice [19,20]. In addition, the presence of 
polyfunctional CD8+ T cells simultaneously secreting IFN-γ 
and IL-2 was found to be associated with natural protection 
against TB and protection following anti-mycobacterial ther-
apy in TB patients [21,22]. In view of these facts, it is expected 
that effective TB vaccines will also elicit polyfunctional T cell 
responses.
 In the development of new TB vaccines, resuscitation-pro-
moting factor (Rpf) is considered a promising target antigen 
[23,24]. Rpfs, first identified in Micrococcus luteus, are bacte-
rial proteins that promote the recovery of bacteria from laten-
cy to a replicating phase [25]. M. tuberculosis expresses five 
different Rpf proteins, RpfA, B, C, D, and E [26], and they have 
resuscitation activity [27,28]. Indeed, deletion of rpf genes re-
sults in delayed reactivation of M. tuberculosis in a murine 
dormancy model [29]. Given that Rpf proteins are expressed 
during growth of M. tuberculosis, Rpfs-specific T cell immu-
nity was expected to be effective in the control of M. tubercu-
losis growth [23,24]. Moreover, Rpfs were shown to be immu-
nogenic in protein [23] or DNA [24] vaccination of mice.
 In the present study, we examined if polyfunctional T cell 
responses are elicited by DNA immunization of M. tuberculo-
sis RpfB. Specifically, we immunized mice with RpfB-encod-
ing plasmid DNA and analyzed the polyfunctionality of T cells. 
Materials and Methods
RpfB DNA plasmid
The rpfB gene of M. tuberculosis H37Rv (NCBI Gene ID: 886048) 
was codon-optimized for mammalian expression and syn-
thesized by GenScript (Piscataway, NJ, USA). The synthesized 
rpfB gene was cloned into the pcDNA3.1(+) mammalian ex-
pression vector (Invitrogen, Carlsbad, CA, USA), where the 
cloned gene is expressed under the control of the cytomega-
lovirus IE-1 promoter. The sequence of the cloned rpfB gene 
was confirmed by sequencing. Large-scale production of plas-
mid DNA was performed using the Plasmid Giga Kit (Qiagen, 
Valencia, CA, USA).
Recombinant RpfB protein
The rpfB gene was amplified by polymerase chain reaction 
from genomic DNA of M. tuberculosis H37Rv and cloned into 
the pET-28a bacterial expression vector (Novagen, Darmstadt, 
Germany), which carries an N-terminal His-tag for protein 
purification. The sequence of the cloned rpfB gene was con-
firmed by sequencing. The RpfB protein was overexpressed 
in BL21 (DE3) Escherichia coli and purified using nickel-nitri-
lotriacetic acid agarose resin. Protein size and purity were con-
firmed by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis. The purity was >90%.
Mouse immunization
Female C57BL/6 mice were housed in a specific pathogen-
free facility in accordance with our institutional guidelines 
and used for immunization at the age of 5-6 weeks. For RpfB 
DNA vaccination, mice were immunized three separate times, 
at 3-week intervals, intramuscularly in both quadriceps mus-
cles with 100 μg of RpfB plasmid DNA. For RpfB protein vac-
cination, mice were immunized three separate times, at 3-week 
intervals, subcutaneously with 50 μg of recombinant RpfB 
(rRpfB) protein. In protein immunization, incomplete Freund’s 
adjuvant (Sigma, St. Louis, MO, USA) was used. For compari-
son, control mice were vaccinated subcutaneously with 2×105 
colony-forming unit of BCG (Pasteur 1173). 
Synthetic peptides
Seventy one pentadecamer peptides (Mimotopes, Clayton, 
Australia), overlapping by 10 amino acids each and spanning 
the complete M. tuberculosis (H37Rv) RpfB protein sequence 
(NCBI Gene ID: 886048) were used. The overlapping peptides 
(OLPs) were resuspended at 20 mg/mL in dimethyl sulfoxide 
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and further diluted to 1 mg/mL with phosphate-buffered sa-
line (PBS). RpfB OLPs were mixed into two separate aliquots. 
The first aliquot included peptides from OLP-1 to OLP-35 
and was designated as OLP mix 1. The other aliquot included 
peptides from OLP-36 to OLP-71 and was designated as OLP 
mix 2. In T-cell assays, either each single OLP or OLP mixes 
were used for T-cell stimulation. 
Indirect enzyme-linked immunosorbent assay 
Serum was collected 4 weeks after the final immunization, 
and anti-RpfB antibody was assessed by indirect enzyme-
linked immunosorbent assay (ELISA). A Maxisorp microtiter 
plate (Nunc, Roskilde, Denmark) was coated with 10 μg/mL 
of rRpfB protein and blocked with 5% fetal bovine serum (FBS)-
0.05% Tween-phosphate buffered saline (PBST). Sera of the 
immunized mice were serially diluted and dispensed into 
each well. After 2 hours of incubation, horseradish peroxi-
dase-conjugated goat anti-mouse IgG (Millipore, Bedford, 
MA, USA) was added. One hour later, color reaction was per-
formed with 3,3´, 5,5´-tetramethylbenzidine (Sigma) for 15 
minutes. The reaction was stopped by 2 M H2SO4, and optical 
density was read at 450 nm.
IFN-γ enzyme-linked immunosorbent spot assay
A 96 well MultiScreen enzyme-linked immunosorbent spot 
(ELISpot) plate (Millipore) was coated with anti-mouse IFN-γ 
antibody (clone AN-18, eBioscience, San Diego, CA, USA). 
The antibody-coated plate was blocked with 1% bovine se-
rum albumin (Bovogen Biologicals, Essendon, Australia). 
Freshly-isolated splenocytes were dispensed into each well 
(500,000 cells/well), and 10 μg/mL of each single OLP was 
added. After 20 hours of incubation, the plate was washed 
with PBS and 0.05% PBST. Biotin-conjugated anti-mouse 
IFN-γ antibody (clone RA-6A2, eBioscience) and alkaline 
phosphatase-streptavidin (BD Pharmingen, San Diego, CA, 
USA) were sequentially added. A color reaction was then per-
formed using AP color reagent (Bio-Rad, Hercules, CA, USA). 
The number of IFN-γ spot forming units was counted using 
an ELISpot reader (Cellular Technology Ltd., Cleveland, OH, 
USA). To evaluate CD8+ and CD4+ T cell responses separately, 
T cells were isolated from splenocytes using CD8 or CD4 mi-
crobeads (Miltenyi Biotec, Auburn, CA, USA), and IFN-γ ELIS-
pot assays were performed with isolated T cells and T cell-
depleted splenocytes [30].
Intracellular cytokine staining and polyfunctional T cell assay
Freshly-isolated splenocytes were resuspended in RPMI 1640 
containing 10% FBS and 2 mM L-glutamine and stimulated 
with a single immunodominant OLP (10 μg/mL), OLP mix (1 
μg/mL for each OLP) or rRpfB protein (5 μg/mL). To evaluate 
cytotoxic degranulation activity of T cells, anti-CD107a-PE-
Cy7 (BD Biosciences, San Jose, CA, USA) was added into the 
culture medium. Brefeldin A (GolgiPlug, BD Biosciences) and 
monensin (GolgiStop, BD Biosciences) were added 2 hours 
later. After another 10 hours of incubation, splenocytes were 
first stained with ethidium monoazide (Sigma) and then stained 
with anti-CD3-V500, anti-CD4-V450 and anti-CD8-APC-H7 
(all from BD Biosciences). The stained cells were permeabi-
lized using Cytofix/Cytoperm kit (BD Biosciences) and then 
stained with anti-IFN-γ-APC, anti-TNF-α-PE and anti-IL-2- 
FITC (all from BD Biosciences). Fluorescence-activated cell 
sorting (FACS) analysis was performed using an LSRII flow 
cytometer (BD Biosciences) and the data were analyzed us-
ing FlowJo software (Treestar, San Carlos, CA, USA). T cells 
positive for the various combinations of cytokines and de-
granulation were analyzed and quantified using a Boolean 
gating function in FlowJo software [31]. 
Results
Humoral immune responses induced by RpfB immunization
First, we assessed the RpfB-specific humoral immune respon-
ses after RpfB immunization. RpfB-specific immunoglobulin 
(Ig) was quantified in serially-diluted sera by indirect ELISA, 
and both DNA and protein immunization of RpfB were found 
to significantly increase the anti-RpfB Ig titer, though protein 
immunization was more potent (Fig. 1). In contrast, anti-RpfB 
Ig was not induced by BCG immunization (Fig. 1). These data 
show that both RpfB DNA and protein are immunogenic and 
capable of eliciting humoral immune responses. 
Identification of the immunodominant T-cell epitopes in RpfB
Next, we identified the immunodominant T-cell epitopes in 
RpfB. Splenocytes were isolated from RpfB DNA-immunized 
mice and stimulated with each of 71 OLPs spanning RpfB fol-
lowed by assessment using an IFN-γ ELISpot assay. IFN-γ 
production was observed by direct ex vivo stimulation fol-
lowing stimulation with OLPs including OLP-14, OLP-30, and 
OLP-51 (Fig. 2A). To identify which T cell subset is responsi-
ble for IFN-γ production following stimulation with each epi-
tope, CD8+ or CD4+ T cells were isolated from splenocytes, 




































Fig. 1. Resuscitation-promoting factor B (RpfB)-specific antibody 
response induced by RpfB immunization. Mice were immunized as 
described in Materials and Methods, and serum collected. The sera 
were serially diluted (1:5,000), and RpfB-specific Ig was measured by 
indirect enzyme-linked immunosorbent assay. BCG, bacillus Calmette-
Guérin. The graph represents mean ± SEM (n = 6). Mann-Whitney U 
test was performed (**p < 0.01). 
Fig. 2. Identification of immunodominant epitope overlapping peptides 
(OLPs) recognized by T cells. Mice were immunized with resuscita-
tion-promoting factor B (RpfB) plasmid DNA as described in Materi-
als and Methods. Splenocytes were obtained from immunized mice, 
and CD8+ and CD4+ T cells were further isolated. Interferon-γ (IFN-γ) 
enzyme-linked immunosorbent spot (ELISpot) assays were performed 
with 500,000 total splenocytes per well (n = 6) (A), 50,000 CD8+ T cells 
per well (n = 3) (B), and 50,000 CD4+ T cells per well (n = 3) (C). In IFN-γ 
ELISpot assays, cells were stimulated with each of 71 OLPs. SFU, spot 






























































and isolated T cells and T cell-depleted splenocytes were sub-
jected to IFN-γ ELISpot assays. OLP-14-stimulated IFN-γ pro-
duction was observed in isolated CD8+ T cells (Fig. 2B), while 
OLP-30- and OLP-51-stimulated IFN-γ production was ob-
served in CD4+ T cells (Fig. 2C). Taken together, OLP-14 (AGV-
QVHDADTIVLRR) is a dominant epitope for CD8+ T cells, 
and OLP-30 (GGLVRTVHLPAPNVA) and OLP-51 (LPVANV-
VVTPAHEAV) are dominant epitopes for CD4+ T cells; how-
ever, it should be noted that the minimal epitope within each 
peptide was not determined. Thus, we used these OLPs for T 
cell stimulation in further analyses.
T cell immune responses elicited by RpfB DNA immunization
We evaluated T cell responses after RpfB immunization by 
intracellular cytokine staining (ICS). In ICS, splenocytes were 
stimulated with OLP mixes or dominant-epitope OLPs, and 
CD4+ and CD8+ T cell responses were separately analyzed by 
gating each subset during FACS analysis. CD4+ T cell respons-
es to OLP mix 1 and OLP mix 2 were potently induced by RpfB 
DNA immunization as shown by IFN-γ ICS whereas they were 
scarcely induced by BCG or RpfB protein immunization (Fig. 
3A). Similar results were observed when cells were stimulat-
ed with the CD4+ T-cell epitopes, OLP-30 and OLP-51 (Fig. 
3A). RpfB DNA immunization also strongly induced RpfB-
specific TNF-α production by CD4+ T cells (Fig. 3B). More-
over, cytotoxic degranulation activity (represented by CD107a) 
of CD4+ T cells was increased following RpfB DNA immuni-
zation (Fig. 3C). However, an IL-2 response was not elicited 
(Fig. 3D).
 In CD8+ T cells, IFN-γ was potently induced in response to 
OLP mix 1 and the CD8+ T-cell epitope OLP-14 following RpfB 
DNA immunization, but not after BCG or RpfB protein im-
munization (Fig. 3E). RpfB DNA immunization also strongly 
induced TNF-α production (Fig. 3F) and cytotoxic degranula-
tion activity (Fig. 3G) of CD8+ T cells whereas an IL-2 response 
was not elicited (Fig. 3H). Cytokine production in response to 
OLP mix 2 was not detected in CD8+ T cells and thus, it is not 
presented.
 Taken together, RpfB DNA immunization induced vigor-
ous responses in both CD4+ and CD8+ T cells, in particular 
IFN-γ and TNF-α production and cytotoxic degranulation ac-
tivity. 
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Fig. 3. Resuscitation-promoting factor B (RpfB)-specific T cell responses induced by RpfB immunization. Mice were immunized as described in 
Materials and Methods, and splenocytes were obtained from immunized mice. Intracellular cytokine staining was performed for interferon-γ 
(IFN-γ) (A, B), tumor necrosis factor-α (TNF-α) (C, D), CD107a (E, F), and interleukin-2 (IL-2) (G, H) after stimulation with the indicated overlap-
ping peptide (OLP) mix or epitope OLP. CD4+ (A, C, E, G) and CD8+ (B, D, F, H) T cell subsets were separately analyzed by gating on each subset 
during luorescence-activated cell sorting analysis. BCG, bacillus Calmette-Guérin. Each bar graph represents mean ± SEM (n = 6). Mann-Whitney 
U test was performed (*p < 0.05, **p < 0.01, ***p < 0.001). 























































































































Polyfunctionality of RpfB­specific T cells
Finally, we assessed the polyfunctionality of RpfB-specific T 
cells by Boolean gating analysis of the ICS data presented in 
Fig. 3. To assess the polyfunctionality of T cells, we analyzed 
four different functions: production of IFN-γ, TNF-α, IL-2 and 
expression of a marker of cytotoxic degranulation activity, 
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Fig. 4. Analysis of the polyfunctionality of resuscitation-promoting factor B (RpfB)-specific T cells induced by RpfB DNA immunization. Rep-
resentative examples of the analysis of polyfunctionality of CD8+ T cells (A, B) and CD4+ T cells (C, D) from an RpfB DNA-immunized mouse 
are presented. Cells were stimulated with overlapping peptide (OLP) mix 1 for the analysis of CD8+ T cells (A, B), and with OLP mix 2 for the 
analysis of CD4+ T cells (C, D). Polyfunctionality for interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin-2 (IL-2), and CD107a was 
assessed. The data are represented by the pie graphs showing the fraction of T cells positive for a given number of functions (A, C). Detailed 






























































CD107a. First, the OLP mix 1-stimulated CD8+ T cell response 
was analyzed after RpfB DNA vaccination, and these CD8+ T 
cells were determined to be polyfunctional as more than half 
of the cells exerted three functions simultaneously (represen-
tative data from a single mouse are presented in Fig. 4A and 
B). The most predominant functional phenotype was that of 
IFN-γ+/TNF-α+/IL-2-/CD107a+ (Fig. 4B), and this polyfunc-
tional T cell response was observed only following RpfB DNA 
immunization, and not following BCG or RpfB protein im-
munization (data not shown). A similar pattern of polyfunc-
tionality was observed against the CD8+ T cell epitope, OLP-
14 (data not shown).
 In CD4+ T cells, the response to the OLP mix 2 was assessed 
for polyfunctionality. Compared to CD8+ T cells, CD4+ T cells 
were less polyfunctional (Fig. 4C). In fact, the most predomi-
nant functional phenotype was that of IFN-γ+/TNF-α+/IL-2-/
CD107a- (Fig. 4D), and more than half of OLP mix 2-specific 
CD4+ T cells were monofunctional (Fig. 4C). However, RpfB 
DNA immunization induced more triple-positive and dou-
ble-positive CD4+ T cells than did BCG or RpfB protein im-
munization (data not shown). A similar pattern of polyfunc-
tionality was observed against OLP mix 1 and the CD4+ T cell 
epitopes, OLP-30 and OLP-51 (data not shown). 
 Thus, all mice immunized with Rpf DNA showed similar 
patterns of T cell polyfunctionality: a highly polyfunctional 




In the present study, we investigated the immunological re-
sponse to M. tuberculosis RpfB DNA immunization. RpfB DNA 
immunization induced not only an RpfB-specific antibody 
response, but also CD8+ and CD4+ T cell responses in mice. 
Further, the induced CD8+ T cell response was determined to 
be polyfunctional as the major population of RpfB-specific 
CD8+ T cells were triple-positive (IFN-γ+/TNF-α+/CD107a+). 
Previously, T cell immunogenicity of Rpf DNA immunization 
was reported [24]; however, T cell polyfunctionality has never 
been studied after Rpf DNA immunization.
 Jino Lee et al • Vaccination with RpfB DNA induces polyfunctional T cells
241http://www.ecevr.org/http://dx.doi.org/10.7774/cevr.2014.3.2.235
 Polyfunctional T cells simultaneously exert multiple func-
tions such as cytokine secretion and cytotoxic activity. Recent-
ly, T cell polyfunctionality has been investigated in several in-
fectious diseases of human and mice. It was reported that 
polyfunctional human immunodeficiency virus (HIV)-spe-
cific CD8+ T cells were maintained in HIV long-term nonpro-
gressors [32]. Furthermore, the degree of Th1 cell polyfunc-
tionality correlated with vaccine efficacy in a Leishmania 
vaccination study [18]. In addition, the efficacy of the small-
pox vaccine has been attributed to polyfunctionality of virus-
specific CD8+ T cells [33]. Further, in a recent primate study, 
polyfunctional hepatitis C virus (HCV)-specific T cells were 
associated with vaccine-induced control of HCV [34]. Taken 
together, the generation of polyfunctional T cells has been 
emphasized in vaccine development. 
 Polyfunctional T cells have been also studied in TB. The 
presence of polyfunctional CD8+ T cells was associated with 
natural protection against TB and protection following anti-
mycobacterial therapy in TB patients [21,22]. Furthermore, 
vaccine-induced polyfunctional CD4+ Th1 cells correlated 
with protection against TB in mice challenged by M. tubercu-
losis [19,20]. Induction of polyfunctional T cells was also prov-
en by experimental TB vaccines in human studies [35-37]. Al-
together, polyfunctional T cells are considered to provide vac-
cine-induced immunity and mediate protection against TB.
 In the present study, RpfB DNA immunization elicited a 
polyfunctional CD8+ T cell response; however, the CD4+ T cell 
response was somewhat less polyfunctional with more than 
half of RpfB-specific CD4+ T cells being monofunctional (Fig. 
4D) in RpfB DNA-immunized mice. Although RpfB DNA im-
munization induced more triple-positive or double-positive 
CD4+ T cells than did BCG or RpfB protein immunization 
(Fig. 4F), this level of polyfunctionality of CD4+ T cells might 
not be sufficient for protection against TB considering the 
importance of the CD4+ Th1 response during TB protection 
[11-14]. Thus in future studies, increasing the polyfunctional-
ity of CD4+ T cells will need to be addressed in order to im-
prove RpfB DNA vaccination. This might be achieved by in 
vivo electroporation during RpfB DNA vaccination as it is 
known that electroporation enhances DNA vaccine-induced 
immune responses [38-40].
 In summary, RpfB DNA immunization elicits polyfunction-
al T cell response, especially in the CD8+ T cell subset, and 
this polyfunctional CD8+ T cell response was dominated by 
the IFN-γ+/TNF-α+/IL-2-/CD107a+ phenotype. These results 
suggest that RpfB DNA immunization might induce protec-
tive immunity against TB, and M. tuberculosis-challenging 
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